½ÃÀ庸°í¼­
»óǰÄÚµå
1587598

¼¼°èÀÇ ÀǾàǰ ÀÚµ¿È­ ½ÃÀå : Á¦Ç°, ¿öÅ©Ç÷οì À¯Çü, ÀÚµ¿È­ ±Ô¸ð, ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº° ºÐ¼® ¹× ¿¹Ãø(-2030³â)

Pharmaceutical Automation Market Forecasts to 2030 - Global Analysis By Product, Workflow Type, Scale of Automation, Technology, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°è ÀǾàǰ ÀÚµ¿È­ ½ÃÀåÀº 2024³â 57¾ï 9,000¸¸ ´Þ·¯¸¦ Â÷ÁöÇÒ Àü¸ÁÀ̰í, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 9.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 94¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.

ÀǾàǰ ÀÚµ¿È­´Â Á¦¾à ¾÷°èÀÇ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­ÇÏ°í °­È­Çϱâ À§ÇÑ ±â¼ú°ú ±â°èÀÇ »ç¿ëÀ» ÀǹÌÇÕ´Ï´Ù. ¿©±â¿¡´Â Á¦Çü, Æ÷Àå, ¶óº§¸µ, ǰÁú °ü¸® µîÀÇ ÀÛ¾÷À» ÀÚµ¿È­Çϰí, È¿À²¼ºÀ» ³ôÀ̰í, ÀÎÀ§Àû ½Ç¼ö¸¦ ÁÙÀ̰í, ±ÔÁ¦ ±âÁØ¿¡ ´ëÇÑ ÄÄÇöóÀ̾𽺸¦ º¸ÀåÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇÕÇÔÀ¸·Î½á Á¦¾à ȸ»ç´Â »ý»ê¼ºÀ» Çâ»ó½ÃŰ°í ¾÷¹« ºñ¿ëÀ» Àý°¨ÇÏ¸ç ±Ã±ØÀûÀ¸·Î ȯÀÚ¿¡°Ô ¾ÈÀüÇϰí È¿°úÀûÀÎ ÀǾàǰÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü¹ÌÁö¿ª¾àÁ¦»çȸ°¡ 2020³â 4¿ù ½Ç½ÃÇÑ Á¶»ç¿¡ µû¸£¸é Áö¿ª¾à±¹ÀÇ ¾à 90%°¡ CARES¹ý¿¡ ±Ù°ÅÇÑ Áß¼Ò±â¾÷¿¬¹æÁ¤ºÎ Áö¿øÀ» ½ÅûÇß½À´Ï´Ù.

¸¸¼º Áúȯ Áõ°¡

´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ¾Ï µîÀÇ ¸¸¼º Áúȯ Áõ°¡·Î È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ ÀǾàǰ Á¦Á¶¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Á¦¾à ȸ»ç´Â Áõ°¡ÇÏ´Â ÀǾàǰ ¿ä±¸¿¡ ºÎÀÀÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸¸ç, ÀÚµ¿È­ ±â¼úÀº Á¦Á¶ °øÁ¤À» °­È­ÇÏ°í ½Å¼ÓÇÑ Á¦Á¶ ¹× ǰÁú °ü¸®¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÚµ¿È­ ½Ã½ºÅÛÀº ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí, ÀÎÀû ½Ç¼ö¸¦ ÃÖ¼ÒÈ­Çϰí, ¸¸¼º Áúȯ °ü¸®¿¡ ÇʼöÀûÀÎ ÀϰüµÈ Á¦Ç° ǰÁúÀ» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

º¹ÀâÇÑ ÅëÇÕ

Á¦¾à ÀÚµ¿È­ÀÇ ÅëÇÕ º¹À⼺Àº ÷´Ü ±â¼úÀ» ±âÁ¸ ½Ã½ºÅÛ ¹× ÇÁ·Î¼¼½º¿Í µ¿±âÈ­ÇÒ Çʿ伺À¸·Î ÀÎÇØ ¹ß»ýÇϸç, ÀÌ´Â ·¹°Å½Ã Àåºñ¿Í ´Ù¾çÇÑ ¼ÒÇÁÆ®¿þ¾î Ç÷§ÆûÀ» Æ÷ÇÔÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÅëÇÕÀº ±â¼úÀûÀ¸·Î ¾î·Á¿ì¸ç ȣȯ¼º°ú È¿À²¼ºÀ» º¸ÀåÇϱâ À§ÇØ »ó´çÇÑ ½Ã°£°ú ÀÚ¿øÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±× °á°ú, ½ÃÀå È®´ëÀÇ ¹æÇذ¡ µÇ°í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü Ä¡·á·ÎÀÇ Àüȯ Áõ°¡

ÀÚµ¿È­ ±â¼úÀ» ÅëÇØ Á¦¾à ȸ»ç´Â »ý»ê ¶óÀÎÀ» ½Å¼ÓÇÏ°Ô ÀûÀÀ½ÃÄÑ È¯ÀÚÀÇ ¿ä±¸¿¡ ¸Â´Â Á¤È®ÇÑ ¿ë¹ý ¹× ¿ë·®À» È®º¸Çϸ鼭 °³º°È­µÈ ÀǾàǰÀ» Á¦Á¶ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ºÀ¸·Î ÀÎÇØ »õ·Î¿î Ä¡·á¹ý ½ÃÀå Ãâ½Ã ½Ã°£ÀÌ ´ÜÃàµË´Ï´Ù. ¶ÇÇÑ Ãà¼ÒµÇ°í ƯÁ¤ ±ÔÁ¦ ¿ä±¸ »çÇ×À» ÃæÁ·½ÃŰ´Â ´É·ÂÀÌ Çâ»óµË´Ï´Ù. ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

³ôÀº Ãʱâ ÅõÀÚ

Á¦¾à ÀÚµ¿È­¿¡ ´ëÇÑ ³ôÀº Ãʱâ ÅõÀڴ ÷´Ü ±â¼ú, Àåºñ ¹× ½Ã½ºÅÛ ÅëÇÕ°ú °ü·ÃµÈ ºñ¿ëÀ¸·Î ÀÎÇØ ÀÚµ¿È­ ¼Ö·ç¼ÇÀ» µµÀÔÇÏ·Á¸é ±â°è, ¼ÒÇÁÆ®¿þ¾î ¹× ÀÎÀû ÀÚ¿ø °³¹ßÀ»À§ÇÑ ¸¹Àº ÀÚº»ÀÌ ÇÊ¿äÇÕ´Ï´Ù., ƯÈ÷ Áß¼Ò±â¾÷¿¡ À־´Â ¹ý¿ÜÀÇ ºÎ´ãÀÌ µË´Ï´Ù.ÀÌ °æÁ¦Àû ºÎ´ãÀÌ ¿ÀÅä¸ÞÀ̼ǿ¡ ´ëÇÑ ÅõÀÚ¸¦ ¾ïÁ¦ÇØ, ½ÃÀå³»ÀÇ ¼ºÀå ±âȸ¸¦ Á¦ÇÑÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19 ÆÒµ¥¹ÍÀº ±â¾÷ÀÌ ÀǾàǰ Á¦Á¶ÀÇ È¿À²È­¿Í ¾ÈÀü¼º È®º¸¸¦ ¿ä±¸Ç߱⠶§¹®¿¡ ÀǾàǰ ÀÚµ¿È­ ½ÃÀåÀ» ÇöÀúÇÏ°Ô °¡¼ÓÈ­Çß½À´Ï´Ù. ¹× AI µîÀÇ ÀÚµ¿È­ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î À̾îÁ³½À´Ï´Ù. Àε¥¹ÍÀº °ø±Þ¸ÁÀÇ Åº·Â¼ºÀ» À¯ÁöÇϱâ À§ÇÑ µðÁöÅÐ Àüȯ°ú ½Ç½Ã°£ µ¥ÀÌÅÍ °ü¸®ÀÇ Á߿伺À» µ¸º¸ÀÌ°Ô Çß½À´Ï´Ù. ¼ö¿ä¿¡ °ßÀÎµÇ°í ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ ºÎ¹®ÀÌ ÃÖ´ë°¡ µÉ Àü¸Á

Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» º¸ÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¡ Çõ¸íÀ» °¡Á®¿É´Ï´Ù. Á¤º¸¿¡ ½Ç½Ã°£ ¾×¼¼½º¸¦ Á¦°øÇÏ°í ¿¬±¸, Á¦Á¶ ¹× ±ÔÁ¦ ÆÀ °£ÀÇ ¿øÈ°ÇÑ Çù¾÷À» ÃËÁøÇÕ´Ï´Ù. ¸¦ ½ÇÇöÇÏ°í °á±¹ ȯÀÚÀÇ °á°ú °³¼±À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È »ý»ê ¹× Á¦Á¶ ºÎ¹®ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

»ý»ê, Á¦Á¶ ºÎ¹®Àº ÀǾàǰ °³¹ß¿¡ À־ÀÇ È¿À²¼º, Á¤È®¼º, ÄÄÇöóÀ̾ð½ºÀÇ Çâ»ó¿¡ ÀÇÇØ ¿¹Ãø ±â°£ Áß¿¡ °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ ¿¹»óµË´Ï´Ù.ÀÚµ¿È­ ½Ã½ºÅÛÀº Á¦Á¦, Æ÷Àå, ¶óº§¸µ, ǰÁú °ü¸® µîÀÇ ÇÁ·Î¼¼½º¸¦ ÇÕ¸®È­, ÀÎÀû ½Ç¼ö¸¦ ÁÙÀ̰í ó¸® ´É·Â Çâ»ó, ¶ÇÇÑ ÀÚµ¿È­¸¦ ÅëÇØ À¯¿¬ÇÑ Á¦Á¶°¡ °¡´ÉÇϹǷΠ±â¾÷Àº º¯È­ÇÏ´Â ½ÃÀå ¼ö¿ä¿Í ¸ÂÃãÇü ÀÇ·á¿¡ ½Å¼ÓÇÏ°Ô ´ëÀÀÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù. ½ÃÀå Ãâ½Ã±îÁö ½Ã°£ ´ÜÃà¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¸¸¼º ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ê¾÷ÀÇ ¼ºÀåÀº ·Îº¿ÀÔ´Ï´Ù. ¿£Áö´Ï¾î¸µ, ÀΰøÁö´É, ¸Ó½Å·¯´×ÀÇ Áøº¸¿Í ÇÔ²² ÀÌ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Çϰí ÀÖ½À´Ï´Ù.

º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ °¡Àå ³ôÀº Áö¿ª :

¿¹Ãø±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. È®½ÇÈ÷ Çϰí ÀÖ½À´Ï´Ù. È­ÀǷᳪ »ý¹°Á¦Á¦ ¼ö¿ä°¡ ³ô¾ÆÁü¿¡ µû¶ó ¿¬±¸°³¹ß¿¡ ÈûÀ» ½ñ°í ÀÖ¾î ÀÚµ¿È­ ±â¼úÀÇ Ã¤¿ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¹ÎøÇÑ Á¦Á¶ °øÁ¤ÀÇ Çʿ伺À» °­Á¶ÇÕ´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌ¡ ¼­ºñ½º :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀû ÇÁ·ÎÆÄÀϸµ(3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ ÀÀÇÑ ÁÖ¿ä±¹ ½ÃÀå Ãß°è, ¿¹Ãø, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(ÁÖ: Ÿ´ç¼º È®Àο¡ µû¸§)
  • °æÀï º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû Á¸Àç, Àü·«Àû Á¦ÈÞ¿¡ ±â¹ÝÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç Á¤º¸¿ø
    • 1Â÷ Á¶»ç Á¤º¸¿ø
    • 2Â÷ Á¶»ç Á¤º¸¿ø
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç°ºÐ¼®
  • ±â¼ú ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾ »ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ÀǾàǰ ÀÚµ¿È­ ½ÃÀå : Á¦Ç°º°

  • ÀÚµ¿È­ ±â±â
    • ·Îº¿ °øÇÐ
    • ¹«ÀÎ ¹Ý¼ÛÂ÷(AGV)
    • ÀÚµ¿ â°í ½Ã½ºÅÛ(AS/RS)
  • ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼Ç
    • Á¦Á¶ ½ÇÇà ½Ã½ºÅÛ(MES)
    • °Ë»ç Á¤º¸ °ü¸® ½Ã½ºÅÛ(LIMS)
    • °ø±Þ¸Á °ü¸® ¼ÒÇÁÆ®¿þ¾î
  • ¼­ºñ½º
    • ÄÁ¼³ÆÃ
    • ÅëÇÕ¼­ºñ½º
    • À¯Áöº¸¼ö ¹× Áö¿ø

Á¦6Àå ¼¼°èÀÇ ÀǾàǰ ÀÚµ¿È­ ½ÃÀå : ¿öÅ©Ç÷οì À¯Çüº°

  • ºÐ¼® Àü
  • ºÐ¼®Àû
  • ºÐ¼® ÈÄ

Á¦7Àå ¼¼°èÀÇ ÀǾàǰ ÀÚµ¿È­ ½ÃÀå : ÀÚµ¿È­ ±Ô¸ðº°

  • ¼öµ¿ ÅëÇÕ
  • ºÎºÐ ÀÚµ¿È­
  • ¿ÏÀü ÀÚµ¿È­

Á¦8Àå ¼¼°èÀÇ ÀǾàǰ ÀÚµ¿È­ ½ÃÀå : ±â¼úº°

  • ÀΰøÁö´É(AI)
  • »ç¹°ÀÎÅͳÝ(IoT)
  • ¸Ó½Å·¯´×
  • Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ
  • µ¥ÀÌÅÍ ºÐ¼®
  • ±âŸ ±â¼ú

Á¦9Àå ¼¼°èÀÇ ÀǾàǰ ÀÚµ¿È­ ½ÃÀå : ¿ëµµº°

  • â¾à
  • ÀÓ»ó½ÃÇè
  • »ý»ê ¹× Á¦Á¶
  • ǰÁú °ü¸® ¹× º¸Áõ
  • ±ÔÁ¦ Áؼö
  • ±âŸ ¿ëµµ

Á¦10Àå ¼¼°èÀÇ ÀǾàǰ ÀÚµ¿È­ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Á¦¾à Á¦Á¶¾÷ü
  • ¼öŹ¿¬±¸±â°ü(CRO)
  • ¼öŹ Á¦Á¶ Á¶Á÷(CMO)
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ¿¬±¸±â°ü
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦11Àå ¼¼°èÀÇ ÀǾàǰ ÀÚµ¿È­ ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦12Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕÀÛ ÅõÀÚ
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦13Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

  • Siemens AG
  • Rockwell Automation Inc.
  • ABB Limited
  • Honeywell International Inc.
  • Emerson Electric Corporation
  • Schneider Electric SE
  • Mitsubishi Electric Corporation
  • Bosch Rexroth AG
  • Yokogawa Electric Corporation
  • Omron Corporation
  • KUKA AG
  • Fanuc Corporation
  • Adept Technology Inc.
  • Parker Hannifin Corporation
  • Datalogic SpA
  • Panasonic Corporation
  • GE Healthcare
  • Ametek Inc.
  • Festo AG & Co. KG
  • B&R Industrial Automation
  • ArisGlobal
  • Beckhoff Automation GmbH
BJH 24.11.15

According to Stratistics MRC, the Global Pharmaceutical Automation Market is accounted for $5.79 billion in 2024 and is expected to reach $9.46 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Pharmaceutical automation refers to the use of technology and machinery to streamline and enhance processes within the pharmaceutical industry. This includes automating tasks such as drug formulation, packaging, labeling, and quality control to improve efficiency, reduce human error, and ensure compliance with regulatory standards. By integrating these technologies, pharmaceutical companies can enhance productivity, reduce operational costs, and ultimately deliver safer and more effective medications to patients.

According to a study conducted by the National Community Pharmacists Association in April 2020, around 90% of community pharmacies were applying for small business federal aid under the CARES Act.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and cancer increases the demand for efficient and scalable drug production. As pharmaceutical companies strive to meet the growing need for medications, automation technologies enhance manufacturing processes, allowing for quicker production and improved quality control. Automated systems can streamline workflows, minimize human error, and ensure consistent product quality, which is crucial for chronic disease management.

Restraint:

Complexity of integration

The complexity of integration in pharmaceutical automation arises from the need to synchronize advanced technologies with existing systems and processes, which often involves legacy equipment and diverse software platforms. This integration can be technically challenging, requiring significant time and resources to ensure compatibility and efficiency. Such complexities can lead to prolonged project timelines, increased costs, and potential disruptions in production. As a result, it impedes the market expansion.

Opportunity:

Growing shift towards customized treatments

Automation technologies enable pharmaceutical companies to quickly adapt production lines to create individualized medications, ensuring precise dosages and formulations tailored to patient needs. This agility in manufacturing reduces time-to-market for new therapies and enhances the ability to meet specific regulatory requirements. Additionally, automated systems improve data management and traceability, essential for tracking personalized treatment outcomes, thereby driving the demand for advanced automation solutions within the pharmaceutical industry.

Threat:

High initial investment

The high initial investment in pharmaceutical automation stems from the costs associated with advanced technologies, equipment, and system integration. Implementing automation solutions requires significant capital for machinery, software, and training personnel, which can be prohibitive, especially for small to mid-sized companies. This financial burden may deter investment in automation, limiting growth opportunities within the market.

Covid-19 Impact

The covid-19 pandemic significantly accelerated the pharmaceutical automation market, as companies sought to enhance efficiency and ensure safety in drug production. The urgent need for vaccines and treatments led to increased investments in automation technologies, such as robotics and AI, to streamline manufacturing processes. Additionally, the pandemic highlighted the importance of digital transformation and real-time data management in maintaining supply chain resilience. As a result, the pharmaceutical automation market is expected to grow, driven by ongoing demand for innovative solutions and improved operational efficiencies.

The cloud computing segment is expected to be the largest during the forecast period

The cloud computing segment is predicted to secure the largest market share throughout the forecast period. Cloud computing technology is revolutionizing pharmaceutical automation by providing scalable and flexible solutions for data storage, management, and analysis. It enables real-time access to critical information, facilitating seamless collaboration among research, manufacturing, and regulatory teams. By leveraging cloud technology, pharmaceutical companies can improve operational efficiency, reduce costs, and accelerate drug development timelines, ultimately leading to better patient outcomes.

The production & manufacturing segment is expected to have the highest CAGR during the forecast period

The production & manufacturing segment is anticipated to witness the highest CAGR during the forecast period fuelled by its enhanced efficiency, accuracy, and compliance in drug development. Automated systems streamline processes such as formulation, packaging, labeling, and quality control, reducing human error and increasing throughput. Automation also facilitates flexible manufacturing, allowing companies to quickly adapt to changing market demands and personalized medicine. Overall, these applications contribute to improved operational efficiency and faster time-to-market for pharmaceuticals.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period driven by rising prevalence of chronic diseases. Countries like China and India are investing heavily in automation technologies. The region's growing pharmaceutical industry, coupled with advancements in robotics, artificial intelligence, and machine learning, is facilitating this transformation. Additionally, the ongoing focus on research and development, along with an expanding biopharmaceutical sector, is further propelling the adoption of automation solutions across the region.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period. The United States and Canada are leading this trend, with investments in robotics, artificial intelligence, and advanced manufacturing systems to enhance operational efficiency and ensure regulatory compliance. The region's strong emphasis on research and development, alongside the rising demand for personalized medicine and biologics, is fueling the adoption of automation technologies. Furthermore, the covid-19 pandemic has accelerated the push towards automation, emphasizing the need for resilient and agile manufacturing processes.

Key players in the market

Some of the key players profiled in the Pharmaceutical Automation Market include Siemens AG, Rockwell Automation Inc., ABB Limited, Honeywell International Inc., Emerson Electric Corporation, Schneider Electric SE, Mitsubishi Electric Corporation, Bosch Rexroth AG, Yokogawa Electric Corporation, Omron Corporation, KUKA AG, Fanuc Corporation, Adept Technology Inc., Parker Hannifin Corporation, Datalogic S.p.A., Panasonic Corporation, GE Healthcare, Ametek Inc., Festo AG & Co. KG, B&R Industrial Automation, ArisGlobal and Beckhoff Automation GmbH.

Key Developments:

In May 2024, ArisGlobal unveiled its enhanced LifeSphere Automation Engine, a significant advancement aimed at revolutionizing the pharmaceutical industry's safety and regulatory processes. This launch emphasizes the integration of artificial intelligence (AI) into the company's existing framework, enabling pharmaceutical organizations to streamline their operations and enhance data management capabilities.

In April 2024, GE Healthcare unveiled its suite of AI-Enhanced Personalized Oncology Solutions. This innovative technology is designed to significantly improve the precision and effectiveness of cancer treatments through advanced automation and machine learning techniques. This personalization is expected to enhance outcomes by aligning therapies more closely with patients' specific cancer profiles.

Products Covered:

  • Automated Equipment
  • Software Solutions
  • Services

Workflow Types Covered:

  • Pre-analytical
  • Analytical
  • Post-analytical

Scale of Automations Covered:

  • Manual Integration
  • Partial Automation
  • Full Automation

Technologies Covered:

  • Artificial Intelligence (AI)
  • Internet of Things (IoT)
  • Machine Learning
  • Cloud Computing
  • Data Analytics
  • Other Technologies

Applications Covered:

  • Drug Discovery
  • Clinical Trials
  • Production & Manufacturing
  • Quality Control & Assurance
  • Regulatory Compliance
  • Other Applications

End Users Covered:

  • Pharmaceutical Manufacturers
  • Contract Research Organizations (CROs)
  • Contract Manufacturing Organizations (CMOs)
  • Biotechnology Companies
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmaceutical Automation Market, By Product

  • 5.1 Introduction
  • 5.2 Automated Equipment
    • 5.2.1 Robotics
    • 5.2.2 Automated Guided Vehicles (AGVs)
    • 5.2.3 Automated Storage & Retrieval Systems (AS/RS)
  • 5.3 Software Solutions
    • 5.3.1 Manufacturing Execution Systems (MES)
    • 5.3.2 Laboratory Information Management Systems (LIMS)
    • 5.3.3 Supply Chain Management Software
  • 5.4 Services
    • 5.4.1 Consulting
    • 5.4.2 Integration Services
    • 5.4.3 Maintenance & Support

6 Global Pharmaceutical Automation Market, By Workflow Type

  • 6.1 Introduction
  • 6.2 Pre-analytical
  • 6.3 Analytical
  • 6.4 Post-analytical

7 Global Pharmaceutical Automation Market, By Scale of Automation

  • 7.1 Introduction
  • 7.2 Manual Integration
  • 7.3 Partial Automation
  • 7.4 Full Automation

8 Global Pharmaceutical Automation Market, By Technology

  • 8.1 Introduction
  • 8.2 Artificial Intelligence (AI)
  • 8.3 Internet of Things (IoT)
  • 8.4 Machine Learning
  • 8.5 Cloud Computing
  • 8.6 Data Analytics
  • 8.7 Other Technologies

9 Global Pharmaceutical Automation Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery
  • 9.3 Clinical Trials
  • 9.4 Production & Manufacturing
  • 9.5 Quality Control & Assurance
  • 9.6 Regulatory Compliance
  • 9.7 Other Applications

10 Global Pharmaceutical Automation Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmaceutical Manufacturers
  • 10.3 Contract Research Organizations (CROs)
  • 10.4 Contract Manufacturing Organizations (CMOs)
  • 10.5 Biotechnology Companies
  • 10.6 Research Institutions
  • 10.7 Other End Users

11 Global Pharmaceutical Automation Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Siemens AG
  • 13.2 Rockwell Automation Inc.
  • 13.3 ABB Limited
  • 13.4 Honeywell International Inc.
  • 13.5 Emerson Electric Corporation
  • 13.6 Schneider Electric SE
  • 13.7 Mitsubishi Electric Corporation
  • 13.8 Bosch Rexroth AG
  • 13.9 Yokogawa Electric Corporation
  • 13.10 Omron Corporation
  • 13.11 KUKA AG
  • 13.12 Fanuc Corporation
  • 13.13 Adept Technology Inc.
  • 13.14 Parker Hannifin Corporation
  • 13.15 Datalogic S.p.A.
  • 13.16 Panasonic Corporation
  • 13.17 GE Healthcare
  • 13.18 Ametek Inc.
  • 13.19 Festo AG & Co. KG
  • 13.20 B&R Industrial Automation
  • 13.21 ArisGlobal
  • 13.22 Beckhoff Automation GmbH
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦